The curse of raised liver enzymes has struck again, with Third Harmonic the latest company to discontinue a phase 1b study of its lead asset over two reports of liver toxicity.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,